Overview
CPG 7909 in Patients With Cutaneous T-Cell Lymphoma
Status:
Completed
Completed
Trial end date:
2007-03-01
2007-03-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
To assess the effect of CPG 7909 Injection on Cutaneous T-cell lymphoma and the safety of CPG 7909 Injection in patients with this cancer.Phase:
Phase 1/Phase 2Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Pfizer
Criteria
Inclusion Criteria:Patients 18 years or older with biopsy (histopathologically) confirmed cutaneous T-cell
lymphoma (limited to mycosis fungoides (MF)) who have had prior therapy with at least one
and no more than 3 systemic treatments.
Exclusion Criteria:
Patients with visceral involvement, serious infection or illness including human
immunodeficiency virus infection, or a Karnofsky Performance Status (KPS) < 60 will be
excluded.